Nondiabetic Kidney Disease
暂无分享,去创建一个
[1] G. Navis,et al. Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism , 2009, Nature Reviews Nephrology.
[2] G. Remuzzi,et al. Proteinuria: Is the ONTARGET renal substudy actually off target? , 2009, Nature Reviews Nephrology.
[3] G. Remuzzi,et al. Proteinuria: Increased angiotensin-receptor blocking is not the first option , 2009, Nature Reviews Nephrology.
[4] G. Remuzzi,et al. Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition. , 2009, The American journal of pathology.
[5] N. Perico,et al. Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection , 2008, Nature Reviews Drug Discovery.
[6] L. Fried. Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease. , 2008, Kidney international.
[7] S. Yusuf,et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial , 2008, The Lancet.
[8] N. Perico,et al. The aggravating mechanisms of aldosterone on kidney fibrosis. , 2008, Journal of the American Society of Nephrology : JASN.
[9] E. Lewis,et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. , 2008, The New England journal of medicine.
[10] J. Ingelfinger. Aliskiren and dual therapy in type 2 diabetes mellitus. , 2008, The New England journal of medicine.
[11] G. Remuzzi,et al. Role of remission clinics in the longitudinal treatment of CKD. , 2008, Journal of the American Society of Nephrology : JASN.
[12] R. Kunz,et al. The COOPERATE trial: a letter of concern , 2008, The Lancet.
[13] S. Mizuno,et al. HGF as a renotrophic and anti-fibrotic regulator in chronic renal disease. , 2008, Frontiers in bioscience : a journal and virtual library.
[14] B. Pussell,et al. Adult nephrotic syndrome: Non‐specific strategies for treatment (Review Article) , 2008, Nephrology.
[15] G. Remuzzi,et al. Intensified inhibition of renin-angiotensin system: A way to improve renal protection? , 2007, Current hypertension reports.
[16] Ping-yan Chen,et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. , 2007, Journal of the American Society of Nephrology : JASN.
[17] G. Remuzzi,et al. How does proteinuria cause progressive renal damage? , 2006, Journal of the American Society of Nephrology : JASN.
[18] M. Tonelli,et al. Statins for improving renal outcomes: a meta-analysis. , 2006, Journal of the American Society of Nephrology : JASN.
[19] G. Remuzzi,et al. ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. , 2006, Kidney international.
[20] G. Remuzzi,et al. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. , 2006, The Journal of clinical investigation.
[21] D. Batlle,et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. , 2005, Kidney international.
[22] G. Striker,et al. Glomerular aging in females is a multi-stage reversible process mediated by phenotypic changes in progenitors. , 2005, The American journal of pathology.
[23] F. Cheema,et al. The renal papilla is a niche for adult kidney stem cells. , 2004, The Journal of clinical investigation.
[24] N. Perico,et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. , 2004, Journal of the American Society of Nephrology : JASN.
[25] Y. Nojima,et al. Identification of renal progenitor-like tubular cells that participate in the regeneration processes of the kidney. , 2003, Journal of the American Society of Nephrology : JASN.
[26] Christopher H Schmid,et al. Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis , 2003, Annals of Internal Medicine.
[27] G. Remuzzi,et al. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. , 2003, Kidney international.
[28] H. Morita,et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. , 2003, Lancet.
[29] G. Remuzzi,et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. , 2003, Kidney international.
[30] H. Morita,et al. RETRACTED: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial , 2003, The Lancet.
[31] G. Remuzzi,et al. Transforming Growth Factor- (cid:1) 1 Is Up-Regulated by Podocytes in Response to Excess Intraglomerular Passage of Proteins A Central Pathway in Progressive Glomerulosclerosis , 2022 .
[32] B. Brenner,et al. Combination ACEI and ARB therapy: additional benefit in renoprotection? , 2002, Current opinion in nephrology and hypertension.
[33] E. Ritz,et al. Smoking and the kidney. , 2002, Journal of the American Society of Nephrology : JASN.
[34] G. Remuzzi,et al. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. , 2002, Kidney international.
[35] M. Bartal. Health effects of tobacco use and exposure. , 2001, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.
[36] M. Okabe,et al. Bone marrow is a reservoir of repopulating mesangial cells during glomerular remodeling. , 2001, Journal of the American Society of Nephrology : JASN.
[37] G. Remuzzi,et al. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. , 2001, Journal of the American Society of Nephrology : JASN.
[38] R. Poulsom,et al. Bone marrow contributes to renal parenchymal turnover and regeneration , 2001, The Journal of pathology.
[39] G. Remuzzi,et al. Progression, remission, regression of chronic renal diseases , 2001, The Lancet.
[40] M. Cooper,et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study , 2000, BMJ : British Medical Journal.
[41] V. D’Agati,et al. Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation. , 2000, Kidney international.
[42] K. Matsumoto,et al. Prevention of renal damage by angiotensin II blockade, accompanied by increased renal hepatocyte growth factor in experimental hypertensive rats. , 1999, Hypertension.
[43] M. Seiki,et al. Regulation of matrix metalloproteinase‐2 (MMP‐2) by hepatocyte growth factor/scatter factor (HGF/SF) in human glioma cells: HGF/SF enhances MMP‐2 expression and activation accompanying up‐regulation of membrane type‐1 MMP , 1999, International journal of cancer.
[44] G. Remuzzi,et al. Pathophysiology of progressive nephropathies. , 1998, The New England journal of medicine.
[45] G. Remuzzi,et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial , 1998, The Lancet.
[46] H. Wedel,et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[47] G. Navis,et al. ACE-inhibitors: panacea for progressive renal disease? , 1997, The Lancet.
[48] F. Locatelli,et al. Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency , 1996 .
[49] G. Beck,et al. The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease , 1994 .
[50] B. Kasiske,et al. Renal injury of diet-induced hypercholesterolemia in rats. , 1990, Kidney international.
[51] N W Shock,et al. Longitudinal Studies on the Rate of Decline in Renal Function with Age , 1985, Journal of the American Geriatrics Society.
[52] C. Mogensen. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. , 1976, Scandinavian journal of clinical and laboratory investigation.
[53] R. Kunz,et al. Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the ReninAngiotensin System on Proteinuria in Renal Disease , 2008, Annals of Internal Medicine.
[54] G. Remuzzi,et al. Halting the progression of renal disease: where we stand? , 2002, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.
[55] W. Keane,et al. Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis. , 1996, Mineral and electrolyte metabolism.